Aprea Therapeutics Inc Aktie News

Unternehmen stärkt globales Portfolio geistigen Eigentums mit 28 erteilten und 30 anhängigen Patenten Unternehmen stärkt globales Portfolio geistigen Eigentums mit 28 erteilten und 30 anhängigen Patenten

Die Einschreibung in die laufende Phase‑1 Dosiseskalationsstudie ACESOT‑1051 des oralen WEE1‑Inhibitors APR‑1051 beschleunigt sich, da die Dosiseskalation voranschreitet

Das nächste klinische Daten‑Update der laufenden Phase‑1‑Dosiseskalationsstudie ACESOT‑1051 wird voraussichtlich auf einer medizinischen Tagung im Q4 2026 vorgestellt und bietet eine kurzfristige Gelegenheit, den fortgesetzten klinischen Fortschritt mit APR‑1051 zu demonstrieren Die Einschreibung in ACESOT‑1051 beschleunigt sich, während das Unternehmen die Dosiseskalation vorantreibt und die k...

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 ...

DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibito...

DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing.

Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients...